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Sleeping sickness, or human African trypanosomiasis (HAT), epitomises the concept of a
“neglected tropical disease” [1]. The history of HAT reads like a Hollywood parody of Homeric
pestilence. Both the chronic and acute forms of HAT are exclusively confined to sub-Saharan
Africa, where they affect the poorest of the rural poor—thriving in weak health systems and con-
flict zones—and where they have been responsible for massive historic epidemics [2]. Both forms
of the disease are invariably fatal if not treated, but available therapies are difficult to administer,
highly toxic, and increasingly pose problems of drug resistance [3]. Diagnostics are complex, and
the procedures needed to sanction the more toxic treatments are difficult, painful, and dangerous,
resulting in massive underreporting [4, 5]. The cunning ability of the causative parasites to evade
the immune system has made a mockery of attempts to develop vaccines, and any continued pro-
testations of a vaccine breakthrough on a meaningful timescale are, at best, wishful thinking [6].
Finally, the hope of control through targeting the disease vector, the tsetse fly, has (for the most
part) eluded cost-effective, sustainable, large-scale delivery [7].
In the face of such challenges, the talk of effective disease control—elimination even—may
at best be thought misplaced optimism and at worst detracting limited resources from a focus
on further research to develop better tools for the future. However, disease elimination is a
stated aim of theWorld Health Organization, and the moral imperative must be to deploy con-
trol tools to save lives now [8]. Successes arising from a small number of well-run programmes
give confidence that even with existing tools, as limited as they may be, effective control—and
in some areas elimination—is a realistic target [9]. The main challenge to realising these bene-
fits is securing the necessary financing to enable appropriately designed interventions to be sus-
tainably delivered at scale immediately [10].
HAT is caused by infectionwith one of two closely related but geographically discrete para-
sites that results in a progressive systemic disease followed by central nervous system damage
and death. In Central and West Africa, disease progression resulting from Trypanosoma brucei
gambiense infection is slow, occurringover many years. By contrast, in East Africa,T. b. rhode-
siense infections progress rapidly, resulting in death within months of infection.While the total
burden of disease is significantly greater for T. b. gambiense than T.b. rhodesiense HAT, where
the latter occurs, local disease burden is much higher than might be expected from its relative
incidence [11].
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Amajor difference between the epidemiology of the two parasites is the importance of non-
human animal hosts in the maintenance and spread of infection. As a goodworking approxi-
mation, T. b. rhodesiense is an infection of animals that occasionally spills over to humans [12],
while T. b. gambiense is a human infection that occasionally resides in animals [13]. Through
understanding this epidemiology, it is now possible to tailor existing tools to maximize benefit
and deliver effective control.
This is what has been successfully done for controlling T. b. rhodesiense in Southeast and
Central Uganda, where livestock (in particular, cattle) have been shown to be of central impor-
tance in the spread of sleeping sickness [14, 15]. Interventions targeted at controlling T. b. rho-
desiense infections in livestock—mass administration of veterinary trypanocidaldrugs followed
up by the routine application of insecticides to protect cattle from tsetse flies—have beenmod-
elled [16, 17] and implemented across large areas of the endemic focus in Uganda following a
resurgence of the disease in the early 2000s [18, 19].
These interventions deliver a double benefit. Firstly, they protect the human population
from sleeping sickness and in so doing shift public health efforts to disease prevention rather
than case finding and treatment. Secondly, they improve livestock health and productivity, as
nonhuman infectious trypanosomes are a major veterinary health burden in sub-Saharan
Africa that significantly affects the productivity of oxen and milking cows and hence rural live-
lihoods [20]. The societal impacts unlocked by delivering these interventions across the wider
endemic areas of East Africa are potentially very large. The economic value that farmers place
on their cattle provides a compelling private incentive to participate in disease control activi-
ties; indeed, it also opens up the potential to developmodels for economic sustainability—over-
coming the failures seen with tsetse control using traps—to incentivise and mobilise
communities over the long term [21].
Ground-breaking work supported by long-term funding from the United KingdomDepart-
ment for International Development (DFID) has been undertaken in Uganda over the last two
decades [14, 15, 16, 17, 18, 19]. The continued expansion of the area in Uganda affected by T.
b. rhodesiense, threatening the integrity of the HAT focus for T. b. gambiense and risking over-
lap of the two forms of HAT, is a strong incentive for action [22]. The public–private alliance
Stamp Out Sleeping sickness, (http://www.stampoutsleepingsickness.com/) delivered highly
cost-effective control throughmass cattle treatments and the development of innovative veteri-
nary drug delivery networks. This prevented the spread of zoonotic HAT and has recently been
named in the top 20 examples of UK further education institutions benefiting global develop-
ment, selected from over 7,000 case studies (see: http://www.ukcds.org.uk/the-global-impact-
of-uk-research/battling-sleeping-sickness). The WHO aims to eliminate sleeping sickness in
Africa by 2030 [23]. The priority now is to scale these validated interventions and attract fund-
ing to allow sustained deployment across the entire region affected by HAT in Uganda.
To achieve this vision, DFID has funded research to explore a novel “impact investment”
approach that could raise the necessary financing for sustained, scaledHAT control. The
approach will build on, and benefit from, the success of GAVI-International Finance Facility
for Immunisation (IFFIm) bonds and other social impact bond initiatives, whereby long-term
public and/or donor commitments to support proven interventions are used to leverage
upfront private sector investment. This financing approach, known as a Development Impact
Bond (DIB), uses “private investment to provide upfront risk capital for development pro-
grammes, only calling on donor funding to repay capital, plus a potential return, once clearly
defined and measured development outcomes are achieved” [24]. The ideal cash flow profile of
the DIB (front-loaded investment followed by long-term lower cash needs) mirrors the high
upfront effort needed to interrupt transmission followed by the reduced effort needed to main-
tain disease control. In poor countries, the money is rarely available to cover these upfront
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costs, and traditional donor grant funding does not advance large amounts of cash; in the DIB,
private investors provide the capital needed upfront, at risk (see Fig 1).
Alongside the cash flow profile, the transfer of risk of programme failure from the donors to
social investors is central to improving the likelihoodof DIB financing over direct funding;
DIBs could bring a greater focus on implementation and delivery of successful results. If the
intervention does not work, the investors lose out. But if it succeeds, international donors
repay the social investors with interest (at a rate below the market rate). In this way, DIBs can
bring greater rigour to delivery of international development and global health interventions—
Fig 1. DIB cash flow and infectious disease control. The graph shows a stylised DIB cash flow profile (annual spend) and the impact on
disease transmission (effective reproductive number, RE). Before the DIB is implemented, the current spend on control (broken black line) is
inadequate to interrupt transmission (RE>1) and shows that in the absence of the additional financing, the disease would persist in an endemic
state (broken red line). The DIB financing is shown by the blue bars and can be broken down into four phases. Preimplementation Phase (Y–1):
detailed design; establishment of surveillance systems; baseline surveys; piloting reporting systems; strengthening of the policy framework.
Suppression Phase (Y1–3): rollout of mass intervention campaigns; flexible, reactive management to achieve critical coverage and to interrupt
transmission (RE<1); routine reporting; audit of intervention coverage. Consolidation Phase (Y4–8): shift from mass intervention to surveillance
and reactive interventions; protection against reintroduction of the disease. Postcontrol Maintenance Phase (Y9–10): Capacity embedded in
local system and ideally fully financed locally. The “front loaded” cash flow profile, which is characteristic of DIB financing, is ideally suited to
infectious disease control and stands in contrast to the traditional flat year-on-year funding. Potential payment triggers for partial repayment of
capital linked to intervention coverage and full capital repayments plus interest based on disease reduction are also shown (grey arrows).
doi:10.1371/journal.pntd.0005000.g001
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investors will only back strategies that have evidence of success. The new instrument could
promote greater scrutiny and operational flexibility to address the realities on the ground in
running the campaign. Under the theoretical scenario outlined in Fig 1, the long-termmainte-
nance of the disease-free state is embedded in local systems and ideally fully financed locally
and affordable within the available budget deployed prior to control. The reality of this long-
term sustainability is amongst many things that still need to be tested by the deployment of an
actual DIB targeted against an NTD.
If a DIB for sleeping sickness can be developed and used to underpin successful disease con-
trol in Uganda, the financing approach could be extended to the other East African nations as
well as the larger problem of T. b. gambiense sleeping sickness in Central and West Africa [13].
Of course, the systems developed through DIB financing to deliver existing interventions can
be adapted to deliver improved control technologies (e.g., new therapeutics [25]) as the evi-
dence base justifies their adoption. However, the broader applicability of DIBs could extend to
the majority of the neglected tropical diseases, where imperfect but adequate disease control
tools already exist.
Rabies is a prime example. The proposed interventions for zoonotic sleeping sickness con-
trol in Uganda share many properties of vaccination campaigns: the need for sensitisation of
communities; the use of existing public health infrastructure capacity to allow routine delivery
of proven interventions at scale; direct benefit(s) seen for the recipients of treatment; nonlinear
benefits unlocked through increased coverage; a focus on prevention rather than reactive treat-
ment; and highly cost-effective interventions and societal level benefits unlocked from deploy-
ment at scale, achieved without having to wait for the vaccine to be developed.However, we do
have vaccines for rabies control—and have had for over 130 years! At the end of 2015, the
WHO and theWorld Organization for Animal Health, in collaboration with the UN Food and
Agriculture Organization and the Global Alliance for the Control of Rabies (GARC), launched
a global framework to eliminate rabies by 2030 [26]. This is supported by the End Rabies Cam-
paign launched by GARC in 2016 at the House of Lords in London, UK.
As with sleeping sickness, the constraints to rabies control are not technical but are rather
the need for public engagement and the mobilization of the necessary financial resources to
support effective operational delivery. The use of DIBs to achieve this, focused on mass vacci-
nation of the domestic dog reservoir combined with the provision of postexposure therapy, is
currently being explored.
Let us not retreat behind the promise of future success from continued research [10]; for
many of the world’s neglected tropical diseases we already have the evidence and the infrastruc-
ture and, with DIBs, a potential financingmodel [27] for their elimination.With the new
Global Goals for Sustainable Development in place, now is surely the time for action.
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